Debra Durso-Bumpus net worth and biography

Debra Durso-Bumpus Biography and Net Worth

Debbie is an accomplished human resources executive with a focus on providing strategic direction to companies on people matters, managing rapid growth and creating and maintaining high performance cultures. Most recently, Debbie served as the interim head of human resources for Cubist Pharmaceuticals, Inc., where she was appointed to lead the post-merger human resource integration following the acquisition of Cubist by Merck. Prior to this role, she was the global senior director for talent management and organizational development at Cubist, where she was primarily responsible for building talent and leadership strength and depth while managing change on a global scale to create a cohesive and highly differentiated culture. Prior to Cubist, Debbie served as the North American manager of talent acquisition and workforce planning at Holcim, Inc., in Waltham, MA. She serves as a member of the board of directors for the Massachusetts Biotechnology Education Foundation, a nonprofit organization committed to supporting science and biotechnology education in Massachusetts through school programs, workforce training and lifelong learning. Debbie earned a B.S. in business management from Bentley University.

What is Debra Durso-Bumpus' net worth?: The estimated net worth of Debra Durso-Bumpus is at least $3.80 million as of August 24th, 2022. Ms. Durso-Bumpus owns 40,836 shares of Blueprint Medicines stock worth more than $3,797,748 as of April 27th. This net worth evaluation does not reflect any other investments that Ms. Durso-Bumpus may own. Learn More about Debra Durso-Bumpus' net worth.
How old is Debra Durso-Bumpus?: Ms. Durso-Bumpus is currently 54 years old. There are 8 older executives and no younger executives at Blueprint Medicines. The oldest executive at Blueprint Medicines is Dr. Christopher K. Murray Ph.D., Senior VP of Technical Operations and Chief Technical Operations & Quality Officer, who is 60 years old. Learn More on Debra Durso-Bumpus' age.
How do I contact Debra Durso-Bumpus?: The corporate mailing address for Ms. Durso-Bumpus and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Debra Durso-Bumpus' contact information.
Has Debra Durso-Bumpus been buying or selling shares of Blueprint Medicines?: Debra Durso-Bumpus has not been actively trading shares of Blueprint Medicines during the last quarter. Most recently, Debra Durso-Bumpus sold 5,000 shares of the business's stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $75.11, for a transaction totalling $375,550.00. Following the completion of the sale, the insider now directly owns 40,836 shares of the company's stock, valued at $3,067,191.96. Learn More on Debra Durso-Bumpus' trading history.
Who are Blueprint Medicines' active insiders?: Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?: In the last twelve months, insiders at the biotechnology company sold shares 24 times. They sold a total of 172,543 shares worth more than $13,714,414.59. The most recent insider tranaction occured on March, 28th when CFO Michael Landsittel sold 5,000 shares worth more than $475,000.00. Insiders at Blueprint Medicines own 3.9% of the company. Learn More about insider trades at Blueprint Medicines.
Information on this page was last updated on 3/28/2024.

Debra Durso-Bumpus Insider Trading History at Blueprint Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/24/2022	Sell	5,000	$75.11	$375,550.00	40,836
6/18/2020	Sell	2,500	$75.18	$187,950.00	22,005

Debra Durso-Bumpus Buying and Selling Activity at Blueprint Medicines

Blueprint Medicines Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $93.00

$90.47

$94.98

50 Day Range

MA: $90.79

$85.18

$99.79

2 Week Range

Now: $93.00

$43.89

$101.00

Volume

725,952 shs

Average Volume

763,933 shs

Market Capitalization

$5.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

Debra Durso-Bumpus Biography and Net Worth

What is Debra Durso-Bumpus' net worth?

How old is Debra Durso-Bumpus?

How do I contact Debra Durso-Bumpus?

Has Debra Durso-Bumpus been buying or selling shares of Blueprint Medicines?

Who are Blueprint Medicines' active insiders?

Are insiders buying or selling shares of Blueprint Medicines?